

# Fibroblast growth factor-10 prevents H<sub>2</sub>O<sub>2</sub>-induced cell cycle arrest by regulation of G1 cyclins and cyclin dependent kinases

D. Upadhyay\*, W. Chang, K. Wei, M. Gao, G.D. Rosen

Division of Pulmonary and Critical Care Medicine, Stanford University Medical Center, 300 Pasteur Drive, Rm H3143, Stanford, CA 94305-5236, USA

Received 24 August 2006; revised 28 November 2006; accepted 7 December 2006

Available online 18 December 2006

Edited by Vladimir Skulachev

**Abstract** We studied the effects of fibroblast growth factor (FGF-10) on H<sub>2</sub>O<sub>2</sub>-induced alveolar epithelial cell (AEC) G1 arrest and the role of G1 cyclins. FGF-10 prevented H<sub>2</sub>O<sub>2</sub>-induced AEC G1 arrest. FGF-10 induced 2–4-fold increase in cyclin E, cyclin A and CDKs (2,4) alone and in AEC treated with H<sub>2</sub>O<sub>2</sub>. H<sub>2</sub>O<sub>2</sub> downregulated cyclin D1; FGF-10 blocked these effects. FGF-10 prevented H<sub>2</sub>O<sub>2</sub>-induced upregulation of CDK inhibitor, p21. siRNAp21 blocked H<sub>2</sub>O<sub>2</sub>-induced downregulation of cyclins, CDKs and AEC G1 arrest. Accordingly, we provide first evidence that FGF-10 regulates G1 cyclins and CDKs, and prevents H<sub>2</sub>O<sub>2</sub>-induced AEC G1 arrest.

© 2006 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

**Keywords:** Fibroblast growth factor-10; G1 Cyclins; H<sub>2</sub>O<sub>2</sub>; p21

## 1. Introduction

Alveolar epithelial cell (AEC) injury and repair are important in the pathogenesis of oxidant-induced lung damage and fibrosis [1–7]. Exposure to oxidants may trigger an intense inflammation and loss of alveolar epithelium. DNA-damaging agents such as H<sub>2</sub>O<sub>2</sub> may induce damage to cellular DNA, lipids, and proteins. Oxidants generate signals that converge to cause wide range of cellular responses ranging from transient growth arrest, to permanent growth arrest, apoptosis and ultimately necrosis, depending on the level of oxidative stress experienced [8–10]. H<sub>2</sub>O<sub>2</sub>, in particular, is known to induce multiphase cell cycle arrest [9]. Control of cell cycle progression in response to oxidative stress is linked to activation of a checkpoint mechanism operating before entry into the S phase of the cell cycle [11–15]. Progression through the G1 phase and the G1–S transition involves sequential assembly and activation of G1 cyclins and cyclin dependent kinases (CDKs) [11–15]. After oxidant injury, the rapidity of initiation of type II cell proliferation is crucial for a proper healing, as delay in the reepithelialization process has been implicated in the development of pulmonary fibrosis [1,3–7]. Therefore,

characterization of the mechanisms involved in the block of type II cell replication by oxidants; and the internal and external stimuli such as antimetabolites and growth factors that regulate the repair mechanisms appear to be critical for the understanding and management of many lung diseases that are associated with oxidative stress.

Fibroblast growth factor-10 (FGF-10) a 19.3 kDa heparin-binding protein, is a potent AEC mitogen that promotes epithelial cell differentiation, migration, wound healing; prevents oxidant (H<sub>2</sub>O<sub>2</sub>, asbestos, cyclic stretch)-induced AEC DNA damage and apoptosis; and is required for lung development [3–7]. The mechanisms underlying the protective effects of FGF-10 are multiple and not well defined. It is known that growth factors and antimetabolites regulate cell cycle in order to integrate recovery from oxidant injury leading to DNA repair and cell division [12–16]. Particularly, bFGF and FGF-2 are shown to modulate cell cycle arrest by regulation of cyclins; however, there is no information on regulation of cell cycle by FGF-10 [12–14]. In this study, we sought to determine whether FGF-10 regulates the cell cycle by restoring the progression of the cell cycle after oxidative stress. We demonstrate that FGF-10 upregulates cyclins and CDKs, downregulates CDK inhibitor, p21 and prevents H<sub>2</sub>O<sub>2</sub>-induced AEC arrest.

## 2. Materials and methods

### 2.1. Materials

FGF-10 was purchased from R&D systems. The antibodies against cyclin E, cyclin A, CDK2, CDK4, cyclin D1, p21, c-Myc and pRb were purchased from Santa Cruz Biotechnology. The anti- $\alpha$ -tubulin monoclonal antibody was purchased from Molecular Probes. All other chemicals were purchased from Sigma Chemicals.

### 2.2. Cell culture

A549 cells were obtained from the American Type Culture Collection and maintained in Dulbecco's modified Eagle's medium (DMEM) containing L-glutamine (0.3  $\mu$ g/ml), non-essential amino acids, penicillin (100 U/ml), streptomycin (200  $\mu$ g/ml), and 10% fetal bovine serum (FBS; GIBCO) in a humidified 95% air–5% CO<sub>2</sub> incubator at 37 °C.

### 2.3. Cell synchronization by serum starvation

Cells were synchronized at G0/G1 phase by serum starvation and then incubated in DMEM with 0.5% bovine calf serum for 48 h, then 10% serum was added to induce the cells to re-enter the cell cycle.

### 2.4. Cell cycle analysis

Cells were synchronized as above, exposed to FGF-10 (10 ng) for 1 h followed by H<sub>2</sub>O<sub>2</sub> (50  $\mu$ M) for 4 h, then trypsinized, harvested, washed with phosphate buffer (PBS), resuspended gently in 5 ml of 90% ethanol and fixed at 25 °C for 1 h. After washing with PBS, the cells were incubated with DNase-free RNase A (200  $\mu$ g/ml) at 37 °C for 1 h,

\*Corresponding author. Fax: +1 650 725 5489.

E-mail address: upadhyay@stanford.edu (D. Upadhyay).

**Abbreviations:** AEC, alveolar epithelial cells; CDK, cyclin dependent kinases; CKI, cyclin dependent kinase inhibitor; FGF-10, fibroblast growth factor-10; siRNA, small interfering RNA p21

washed with PBS and then incubation with Propidium iodide (10  $\mu\text{g}/\text{ml}$ ) at 37 °C for 5 min. Cells were separated by sonicating at 20% output level for 15 s using a VirSonic 50 sonicator (Vitis), sorted by fluorescence-activated cell sorter (FACS) and analyzed using FlowJo (version 3.0.3) (Tree Start).

### 2.5. [<sup>3</sup>H]Thymidine incorporation assay

Cells were treated with FGF-10 followed by H<sub>2</sub>O<sub>2</sub>, incubated with [<sup>3</sup>H]Thymidine (1  $\mu\text{Ci}/\text{ml}$  [<sup>3</sup>H]-TdR) for 6 h and washed once with PBS. Then cells were incubated with 10% trichloroacetic acid (TCA) solution twice for 5 min each at 4 °C followed by 10% SDS for 2 min at room temperature. The amount of radioactivity was quantified in a scintillation counter.

### 2.6. MTT cell viability assay

Cells were treated with FGF-10 followed by H<sub>2</sub>O<sub>2</sub> and incubated with MTT (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide, disodium salt) (20  $\mu\text{l}$ ) for 3 h. An absorbance at 490 nm was measured to quantify the amount of formazan product.

### 2.7. Western blot analysis

Cells were treated, washed and lysed. Proteins were size fractionated by 10% gel electrophoresis and transferred to nitrocellulose membranes using a semi-dry transfer (Bio-Rad). Blots were incubated with cyclin- and CDK-specific antibodies overnight at 4 °C and developed with an enhanced chemiluminescence detection kit (Amersham). The bands were quantified by densitometric scan NIH Image 1.62.

### 2.8. Kinase assay

Two hundred micrograms of protein lysate was immunoprecipitated with 1–2  $\mu\text{g}$  of anti-cyclin E antibody or anti-CDK2 antibody and incubated at 4 °C overnight. Cyclin-CDKs were isolated by incubation at 4 °C for 1 h with 50  $\mu\text{l}$  of GSH-agarose beads (Pharmacia) and beads were washed. Five hundred nanograms of histone H1, 20  $\mu\text{M}$  ATP and 0.1  $\mu\text{Ci}$  of [ $\gamma$ -<sup>32</sup>P] ATP (3000 Ci/mmol; Amersham) were added in 20  $\mu\text{l}$  of assay buffer and incubated for 30 min at 37 °C. The reaction was terminated by sample buffer (50  $\mu\text{l}$ ) and boiling for 3 min. The samples were resolved on 12% gel, fixed, Coomassie-stained, dried and then exposed to a PhosphorImager screen.

### 2.9. ELISA

p21 ELISA was performed by using TiterZyme ELISA Kits from Assay Designs as per the manufactures protocol.

### 2.10. Statistics

Data are reported as means  $\pm$  S.E.M. Statistical analysis was done by one-way ANOVA and Tukey tests. Results were considered significant when  $P < 0.05$ .

## 3. Results and discussion

Given the important role of growth factors in the regulation of cell cycle, and the role of FGF-10 in the prevention of oxidant-induced AEC DNA damage and apoptosis, we determined the effects of FGF-10, a potent AEC mitogen, on the regulation of G1 cyclins and CDKs on H<sub>2</sub>O<sub>2</sub>-induced AEC arrest [1–7]. Barnouin et al. recently described that a sublethal dose of H<sub>2</sub>O<sub>2</sub> induces transient multi-phase cell cycle arrest [9]. Using this study model, we observed that FGF-10 attenuates H<sub>2</sub>O<sub>2</sub>-induced AEC arrest in G1 by FACS with propidium iodide staining (Fig. 1a). In this study, we focused on examining the effect of FGF-10 in G1 phase. Cell cycle analysis after starvation of AEC for 48 h revealed 92.2% cells were in G0/G1, with 5.43% in S and 2.37% in G2/M (Fig. 1a). H<sub>2</sub>O<sub>2</sub> (50  $\mu\text{M}$ ) for 4 h did not affect the cell cycle distribution of starved AEC but prevented serum-induced G1 to S progression; however, pretreatment with FGF-10 (10 ng) for 1 h




Fig. 1. (a) FGF-10 attenuates H<sub>2</sub>O<sub>2</sub>-induced AEC cycle G1 arrest: cell cycle analysis was performed by FACS with propidium iodide. Upon starvation for 48 h, 92.3% cells were in G0/G1, with 5.43% in S and 2.37% in G2/M. Addition of H<sub>2</sub>O<sub>2</sub> (50  $\mu\text{M}$ ) for 4 h alone after serum stimulation did not change this distribution. However, pretreatment with FGF-10 (10 ng) for 1 h prevented H<sub>2</sub>O<sub>2</sub>-induced AEC arrest in G1 phase. Means  $\pm$  S.E.M.,  $n = 3$ . † $P < 0.05$  control vs. H<sub>2</sub>O<sub>2</sub>, ‡ $P < 0.05$  H<sub>2</sub>O<sub>2</sub> vs. FGF-10 + H<sub>2</sub>O<sub>2</sub>. (b and c): Effect of FGF-10 on AEC DNA synthesis and proliferation: although FGF-10, at 24 h induced 1/2–1-fold increase in DNA synthesis and cell proliferation in cells exposed to H<sub>2</sub>O<sub>2</sub>; it had no effect on [<sup>3</sup>H]Thymidine uptake or MTT counts at 1 h. Means  $\pm$  S.E.M., \* $P < 0.05$  control vs. H<sub>2</sub>O<sub>2</sub>, † $P < 0.05$  FGF-10 1 h vs. 24 h, ‡ $P < 0.05$  H<sub>2</sub>O<sub>2</sub> vs. FGF-10 + H<sub>2</sub>O<sub>2</sub>,  $n = 3$ .

moved 27  $\pm$  2.7% cells to S, 12.8% to G2/M while 60.2  $\pm$  4.6% cells remained in G0/G1. Following exposure to FGF-10 alone, 44.1  $\pm$  2.9% cells moved to S/G2/M while 56.9  $\pm$  2.1% cells remained in G0/G1. These data suggest that H<sub>2</sub>O<sub>2</sub> prevents progression of cell cycle by causing arrest in G0/G1 and FGF-10 attenuates these effects. Further, we found that FGF-10 did not affect [<sup>3</sup>H]Thymidine uptake or AEC proliferation after 1 h exposure; however, augmented DNA synthesis and improved cell viability by MTT assays was observed at 24 h in AEC exposed to FGF-10 alone and with H<sub>2</sub>O<sub>2</sub> (Fig. 1b, c).

The cell cycle progression is controlled by the cooperative activity of the cyclins and CDKs (Fig. 4) [17–20]. G1–S transition is regulated by cyclin E in association with its catalytic partner CDK2; this is a rate limiting step for entry into the

S phase [16–20]. bFGF and FGF-2, both, upregulate cyclins and CDKs [12,13]. Although growth factors are known inhibit G1 arrest and apoptosis via mitogen activated protein kinases

(MAPK), sustained protection against G1 arrest and apoptosis by bFGF was shown to occur by inhibition of CDK inhibitor [4,6,12,13]. We previously showed that MAPK mediate the




Fig. 2. FGF-10 attenuates H<sub>2</sub>O<sub>2</sub>-induced AEC G1 arrest by upregulation of positive cell cycle regulatory cyclins and CDKs: we analyzed the effect of FGF-10 and H<sub>2</sub>O<sub>2</sub> on G1 cyclins and CDKs by Western blot. H<sub>2</sub>O<sub>2</sub> decreased total- and phosphorylated-cyclin E in AEC. Pretreatment of AEC with FGF-10 increased phosphorylated-cyclin E (a), cyclin A (b), CDK2 and CDK4 (c) alone as well as in AEC exposed to H<sub>2</sub>O<sub>2</sub>, while H<sub>2</sub>O<sub>2</sub> did not. H<sub>2</sub>O<sub>2</sub> caused down regulation of cyclin D1 in AEC and FGF-10 prevented these effects (b). FGF-10 increased CDK2 and cyclin E kinase activity in AEC alone and in the cells exposed to H<sub>2</sub>O<sub>2</sub>, while H<sub>2</sub>O<sub>2</sub> did not, cmyc and pRb were unchanged (e). Means ± S.E.M., n = 3. \*P < 0.05 control vs. FGF-10; <sup>‡</sup>P < 0.05 control vs. H<sub>2</sub>O<sub>2</sub>; <sup>†</sup>P < 0.05 H<sub>2</sub>O<sub>2</sub> vs. FGF-10 + H<sub>2</sub>O<sub>2</sub>.




Fig. 3. FGF-10 prevents H<sub>2</sub>O<sub>2</sub>-induced upregulation of CDK inhibitor, p21 in AEC: H<sub>2</sub>O<sub>2</sub> (50 μM) induces 11/2–2-fold increase in p21 while FGF-10 blocks H<sub>2</sub>O<sub>2</sub>-induced increase in p21 as assessed by Western blot (a) and ELISA (b, assay designs). \**P* < 0.05 control vs. H<sub>2</sub>O<sub>2</sub>; †*P* < 0.05 H<sub>2</sub>O<sub>2</sub> vs. FGF-10 + H<sub>2</sub>O<sub>2</sub>, *n* = 3. SiRNAp21 prevents H<sub>2</sub>O<sub>2</sub>-induced downregulation of cyclin E, D1, CDK2 (c) and AEC arrest (d); however, dose not affect effects of FGF-10. \**P* < 0.05 control vs. H<sub>2</sub>O<sub>2</sub> (Scramble); †*P* < 0.05 H<sub>2</sub>O<sub>2</sub> (Scramble) vs. H<sub>2</sub>O<sub>2</sub> (SiRNAp21) G1 Phase; ‡*P* < 0.05 H<sub>2</sub>O<sub>2</sub> (Scramble) vs. H<sub>2</sub>O<sub>2</sub> (SiRNAp21) G2/M Phase; *n* = 3.

protective effect of FGF-10 against AEC apoptosis [4,6]. In this study, we show that, FGF-10 prevents H<sub>2</sub>O<sub>2</sub>-induced decrease in total- and phosphorylated cyclin E, induces 21/2-fold increase in phosphorylated cyclin E and 31/2-fold increase in cyclin A in AEC alone and in cells exposed to H<sub>2</sub>O<sub>2</sub>, while, H<sub>2</sub>O<sub>2</sub> alone does not affect either (Fig. 2a, b). H<sub>2</sub>O<sub>2</sub> causes downregulation of cyclin D1, while pretreatment of AEC with FGF-10 prevents these effects (Fig. 2b). FGF-10 induces 2–21/2-fold increase in CDK2 and CDK4 as assessed by Western blot (Fig. 2c) and increases CDK2 and cyclin E kinase activity in AEC alone as well as in the cells exposed to H<sub>2</sub>O<sub>2</sub>, while H<sub>2</sub>O<sub>2</sub> does not (Fig. 2d); cmyc and pRb remain unchanged (Fig. 2e). These data suggest that FGF-10 upregulates forward cell cycle regulatory cyclins (E, D1, A) and CDKs (2, 4), prevents downregulation of cyclin D1 in AEC exposed to H<sub>2</sub>O<sub>2</sub> and promotes cell cycle progression after oxidative stress.

p21 is a G1-specific CDK inhibitor (CKI) that prevents cell cycle progression by causing inhibition of cyclins, CDKs, the cyclin-CDK2 complex activity and transcription factors (E2F, retinoblastoma protein and proliferator cell nuclear antigen) [20–22]. Increased expression of CKIs attenuates




Fig. 4. Schematic diagram of FGF signaling pathways involved in the regulation of cell cycle, cyclins and CDKs.

FGF-2-stimulated cell proliferation [12]. Oxidative stress is known to induce p21; therefore we examined role of p21 in H<sub>2</sub>O<sub>2</sub>-induced AEC arrest [22]. We found that H<sub>2</sub>O<sub>2</sub> causes 11/2–2-fold increase in p21 and pretreatment of AEC with FGF-10 blocks these effects (Fig. 3a, b). Further, abrogation of p21 expression by small interfering RNA (siRNA) targeting in AEC prevents H<sub>2</sub>O<sub>2</sub>-induced downregulation of cyclins and CDKs, and prevents H<sub>2</sub>O<sub>2</sub>-induced AEC arrest; however, dose not change FGF-10-induced regulation of cyclins and CDKs (Fig. 3c, d). Collectively, these data suggest that the protective effects of FGF-10 against H<sub>2</sub>O<sub>2</sub>-induced G1 arrest, in part, are mediated by the inhibition of H<sub>2</sub>O<sub>2</sub>-induced p21 in AEC.

In summary, we show for the first time that FGF-10 regulates AEC G1 cyclins and CDKs. The induction of forward cell cycle regulatory cyclins and CDKs and inhibition of p21 by FGF-10 may have a role in mediating the protective effects of FGF-10 against H<sub>2</sub>O<sub>2</sub>-induced AEC arrest. We recently showed that FGF-10 protects against oxidant-induced DNA damage and apoptosis in AEC and these data coupled with our findings here show that FGF-10 regulates oxidant-induced lung injury both by inhibiting oxidant-induced growth arrest and by inhibiting apoptosis.

*Acknowledgements:* Supported in part by HL010487 and ALA-Research Grant (D.U.).

**References**

- [1] Wu, K.I., Pollack, N., Panos, R.J., Sporn, P.H. and Kamp, D.W. (1998) Keratinocyte growth factor promotes alveolar epithelial cell DNA repair after H<sub>2</sub>O<sub>2</sub> exposure. *Am. J. Physiol.* 275, L780–L787.
- [2] Uhal, B.D. (1997) Cell cycle kinetics in the alveolar epithelium. *Am. J. Physiol.* 272, L1031–L1045.
- [3] Mason, J., Rampy, M.A., McCormack-Shannon, K., Edeen, K., Okoye, Z. and Shannon, J.M. (1999) FGF-10 is a mitogen for adult rat type II cells. *Am. J. Respir. Crit. Care Med.* 159, A172.
- [4] Upadhyay, D., Meyer, E.C., Sznajder, J.I. and Kamp, D.W. (2003) FGF-10 attenuates cyclic stretch-induced alveolar epithelial cell DNA damage via MAPK/ERK pathway. *Am. J. Physiol.* 284, L350–L359.

- [5] Upadhyay, D., Bundesman, M., Panduri, V., Correa-Meyer, E. and Kamp, D.W. (2004) FGF-10 attenuates H<sub>2</sub>O<sub>2</sub>-induced alveolar epithelial cell DNA damage: role of MAPK activation and DNA repair. *Am. J. Respir. Cell Mol. Biol.* 31, 107–113.
- [6] Upadhyay, D., Panduri, V. and Kamp, D.W. (2005) FGF-10 attenuates asbestos-induced alveolar epithelial cell DNA damage and Apoptosis via MAPK pathway. *Am. J. Respir. Cell Mol. Biol.* 32, 232–238.
- [7] Deterding, R.R., Havill, A.M., Yano, T., Middleton, S.C., Jacoby, C.R., Shannon, J.M., Simonet, W.S. and Mason, R.J. (1997) Prevention of bleomycin-induced lung injury in rats by keratinocyte growth factor. *Proc. Assoc. Am. Physician* 109, 254–268.
- [8] Henle, E.S. and Linn, S. (1997) Formation, prevention, and repair of DNA damage by iron/hydrogen peroxide. *J. Biol. Chem.* 272, 19095–19098.
- [9] Barnouin, K., Dubuisson, M.L., Child, E.S., Fernandez de Mattos, S., Glassford, J., Medema, R.H., Mann, D.J. and Lam, E.W.F. (2002) H<sub>2</sub>O<sub>2</sub> induces a transient multi-phase cell cycle arrest in mouse fibroblasts through modulating cyclin D and p21Cip1 expression. *J. Biol. Chem.* 277, 13761–13770.
- [10] Bartek, J. and Lukas, J. (2001) Pathways governing G1/S transition and their response to DNA damage. *FEBS Lett.* 490, 117–122.
- [11] Igarashi, M., Finch, P.W. and Aaronson, S.A. (1998) Characterization of recombinant human fibroblast growth factor (FGF)-10 reveals functional similarities with keratinocyte growth factor (FGF-7). *J. Biol. Chem.* 273, 1320–1325.
- [12] Olson, N.E., Kozlowski, J. and Reidy, M.A. (2000) Proliferation of intimal smooth muscle cells: attenuation of bFGF-2-stimulated proliferation is associated with increased expression of cell cycle inhibitors. *J. Biol. Chem.* 275, 11270–11277.
- [13] Liu, B., Fang, M., Lu, Y., Mendelsohn, J. and Fan, Z. (2001) Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. *Oncogene* 20, 1913–1922.
- [14] Hulleman, E. and Boonstra, J. (2001) Regulation of G1 phase progression by growth factors and the extracellular matrix. *Cell Mol. Life Sci.* 58, 80–93.
- [15] Tanno, V.J., Hinds, P.W. and Tsai, L.H. (2000) Cell cycle control. *Adv. Exp. Med. Biol.* 465, 127–140.
- [16] Ekholm, S.V. and Reed, S.I. (2000) Regulation of G1 cyclin-dependent kinases in the mammalian cell cycle. *Curr. Opin. Cell Biol.* 12, 676–684.
- [17] Clement, A., Henrion-Caude, A., Besnard, V. and Corroyer, S. (2001) Role of cyclins in epithelial response to oxidants. *Am. J. Respir. Crit. Care Med.* 164, S81–S84.
- [18] Corroyer, S., Maitre, B., Cazals, V. and Clement, A. (1996) Oxidant-induced growth arrest of alveolar epithelial cells involves inactivation of cyclin E-CDK2 complex. *J. Biol. Chem.* 271, 25117–25125.
- [19] Desai, D., Wessling, H.C., Fisher, R.P. and Morgan, D.O. (1995) Effects of phosphorylation by CAK on cyclin binding by CDC2 and CDK2. *Mol. Cell Biol.* 15, 345–350.
- [20] Sherr, C.J. and Roberts, J.M. (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. *Genes Dev.* 13, 1501–1512.
- [21] Mattock, H., Lane, D.P. and Warbrick, E. (2001) Inhibition of cell proliferation by the PCNA-binding region of p21 expressed as a GFP mini protein. *Exp. Cell Res.* 265, 234–241.
- [22] O'Reilly, M.A., Staversky, R.J., Watkins, R.H. and Maniscalco, W.M. (1998) Accumulation of p21 during hyperoxic lung injury in mice. *Am. J. Respir. Cell Mol. Biol.* 19, 777–785.